- $515.24m
- $476.83m
- $82.71m
- 47
- 18
- 67
- 40
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.23 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -44.55% | ||
| Return on Equity | n/a | ||
| Operating Margin | -79.23% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.02 | 11.8 | 48.04 | 64.36 | 82.71 | 99.3 | 186.05 | 136.08% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).
Directors
- Arie Belldegrun NEC (71)
- Elizabeth Barrett PRE (58)
- Molly Henderson CFO (51)
- Jason Smith CCO (49)
- Mark Schoenberg OTH (63)
- Cynthia Butitta IND (66)
- Fred Cohen IND (64)
- Kathryn Falberg IND (60)
- Stuart Holden IND (78)
- Ran Nussbaum IND (48)
- Shawn Tomasello IND (62)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 28th, 2004
- Public Since
- May 4th, 2017
- No. of Shareholders
- 16
- No. of Employees
- 198
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 34,122,087
- Address
- 9 Ha'ta'asiya St, RA'ANANA, 4365007
- Web
- https://www.urogen.com/
- Phone
- +972 97707601
- Contact
- Vincent Perrone
- Auditors
- PricewaterhouseCoopers LLP
Upcoming Events for URGN
Q2 2024 Urogen Pharma Ltd Earnings Release
Urogen Pharma Ltd Annual Shareholders Meeting
Similar to URGN
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Adagene
NASDAQ Global Market
FAQ
What is the Urogen Pharma share price?
As of Today at 19:23 UTC, shares in Urogen Pharma are trading at $15.10. This share price information is delayed by 15 minutes.
How has the Urogen Pharma share price performed this year?
Shares in Urogen Pharma last closed at $15.10 and the price had moved by +53.3% over the past 365 days. In terms of relative price strength the Urogen Pharma share price has outperformed the S&P500 Index by +23.8% over the past year.
What are the analyst and broker recommendations for Urogen Pharma?
The overall consensus recommendation for Urogen Pharma is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Urogen Pharma dividend yield?
Urogen Pharma does not currently pay a dividend.
Does Urogen Pharma pay a dividend?
Urogen Pharma does not currently pay a dividend.
When does Urogen Pharma next pay dividends?
Urogen Pharma does not currently pay a dividend.
How do I buy Urogen Pharma shares?
To buy shares in Urogen Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Urogen Pharma?
As of the previous close price of $15.10, shares in Urogen Pharma had a market capitalisation of $515.24m.
Where are Urogen Pharma shares listed?
Here are the trading details for Urogen Pharma:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: URGN
What kind of share is Urogen Pharma?
Based on an overall assessment of its quality, value and momentum Urogen Pharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Urogen Pharma share price forecast for 2024?
The analyst consensus target price for shares in Urogen Pharma is $38.50. That is 154.97% above the last closing price of $15.10.
Analysts covering Urogen Pharma currently have a consensus Earnings Per Share (EPS) forecast of -$3.65 for the next financial year.
What is the trend in the Urogen Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Urogen Pharma. Over the past six months, its share price has underperformed the S&P500 Index by -1.6%.
As of the last closing price of $15.10, shares in Urogen Pharma were trading +0.84% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Urogen Pharma PE Ratio?
The Urogen Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $15.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Urogen Pharma?
Urogen Pharma's management team is headed by:
- Arie Belldegrun - NEC
- Elizabeth Barrett - PRE
- Molly Henderson - CFO
- Jason Smith - CCO
- Mark Schoenberg - OTH
- Cynthia Butitta - IND
- Fred Cohen - IND
- Kathryn Falberg - IND
- Stuart Holden - IND
- Ran Nussbaum - IND
- Shawn Tomasello - IND